Member Info for CHELSEA7

Afternoon Inan, I have asked a few times, but any ideas as to timelines for news in the CIB1/Keytruda trial?

Morning, all about the timing, and a very exciting time.

Deadly, I really get your anger, for all the rows we have had here over the years, hopefully this one will be the last for a very long time.

I filtered Knowlesi a couple of weeks back simply because the lies were really getting to me, a BB, any BB shouldn"t be about that. I actually concluded something was very wrong with the venom and anger expressed on here to just about everybody. If knowlesi comes back that is his choice, but this is as close to a username suicide we will ever see..........................so lets move on. This is not about a difference of opinion it runs much deeper.

Next week should be about Scancell back in trials, the SP is a seperate issue, but as Martin Diggle says, which we have all just about been saying for a very long time, Scancell is undervalued. I have said a few times in the last couple of years that the one thing we haven"t been blessed with is luck, looks like that is changing too. Have a good weekend guys and Knowlesi take it easy. Night

Boogles, welcome aboard the good ship Scancell too!!

Interesting Article, I think advocadoes and kiwi fruit will go down well at the AGM!!

Morning Crumbs, well I took off my filter about 3.00a.m, and thought i might as well look back on the last ten days or so of postings by Knowlesi. The filter is back on now, and very happy I finally had the sense to put it on in the first place. Nothing has changed except each post seems to come across more bitter, more argumentative, ruder, not a post bears the hallmark of IMHO, and last nights one I actually laughed at, which was timely due to a very bad night.

So Chris Holloway confirms on Proactive 9 days ago that the SCIB1/Keytruda trial WILL begin by the end of this month and Knowlesi believes that is not the case. Hmmm.

"""BioNtech or bust - We've gone from 10's of NDA's to just BioNtech, they going to pay top dollar ?"""

Well after listening to the Martin Diggle interview also with Proactive we learnt that their interest began in 2013, which is another reminder how long it can take for deals of any nature to complete, besides Karolinska are in the frame and who is to say there is no other party involved in serious discussions with us? I wasn"t aware we had 10 NDAs in place, nor have nine been rejected, but of course that is just another example of posting as if it is a fact, and bingo that means only Biontech are an option. If anything after learning how long Martin Diggle has been following Scancell, my most immediate thought was I wonder just who else we have been in deep discussions with, it could be anybody.

Trial numbers are too small? Well i suppose knowing that Martin Diggle wrote a cheque out for nigh on £4m on the strength of that, and some nonsense about salaries being too much. Well to attract the best and to have increased our staff to 23, 12 of which have PhDs, we seem to be hand picking key personnel, and it would be a great idea to reduce LDs package to around £30k a year as an incentive, lol. Can"t remember the rest, I just want to thank Knowlesi for saying more about himself than any of us could say about him.

Well more than enough on that, just strikes me as being very obvious that these posts are being timed to divert from good feelings which are spreading and delighted so many newbies and LTH have had the opportunity to buy shares as low as the mid 3"s in recent weeks, whether it be for a quick return , build a decent holding or to drastically lower averages.

I actually listened to Martin Diggles interview a couple of times during the night, he inspires confidence and seems a perfect fit. I do not think for a second he is concerned about the SCIB1 trial being delayed or the cohorts being too small, lol.

Was just reading back on a few posts and your 16.22 mirroredd my thoughts....................

""It was also nice to get that interview... from a pr aspect which many here have felt is not always the best.... maybe this will be something we now notice improving with Martin on the BOD.... A proactive investor with clout!"""

I mentioned that earlier by suggesting perhaps now is the time to start seeing PR directed at PIs. There are so many avenues of news as reminded by Inanaco in an earlier post too........................

Homocittruline
Glycans
ISA Pharma brilliant adjuvant
Synergy with Keytruda
CRUK
Karolinska
TCR

And lets not forget news on Biontech too due this month as to lengthening our collaboration or perhaps even a commercial deal, as is the case with Karolinska, three years working together now. Just adding to that list news of SCIB1/2 trials and of course MOD1. As has been the case recently we have had a seriesof good news, and the inflection based news has so much scope to continue, free from worries about funding, and todays M/Cap of £31m could easily see us return to £50m on any number of items.

Can"t remember a time where the pathway has been so clear before and next week as we know are the last five business days in June. We have seen a decent consolidation of recent rises this week, with the bid strongly rebounding from 6p to 6.50p, I just have a feeling we are ready to move North again, and a return to double figures doesn"t seem so far off now.''Working on adrenalin now, so time to sleep, with the knowledge we have never been better positioned as we are now.

The difference................................

https://www.nedonboard.com/what-are-the-key-differences-between-executive-and-non-executive-directors/

Last post guys, I seem to have woken up for the first time this week.

Does anybody know, our cash position, obviously including the £3.9m from Vulpes, any tax credits we were due added to the remaining balance prior to the Vulpes deal? Would be onlty too happy to know that, I have lost count.

It wasonly a few weeks ago that Chris Holloway made a point of mentioning the AIM market as being perhaps the hardest hurdle that has faced us in recent times. Martin Diggle continued on that line with his observation that America values Biotechs far better than we do in England.

A subject we have debated many times is the possibility of us list ing in an appropiatr American market. The costs involved in doing so are prohibitive, as is the argument it is by no means a certainty that being listed there attracts investors to a pretty much unknown British Biotech.

This is why IMHO gaining Approval for the U,S, arm of the SCIB1 trial has never been so important from the FDA. We have many experts on side there, particularly Keith Flaherty whose support for us has not waivered at all. Adding it all up, I can see in the next coupole of years moves by us to list over there will happen, when the time is right.

What has come very clearly from Martin Diggles comments is the huge discrepancy in valuations across the divide and for a fund now holding 17% of Scancell and paid for in £4m cash it is a move which is very much on the cards.

Anybody have any thoughts on that?

So just continuing pandas posts about feeling very relaxed with his investment and does seem that in all areas we have improved our in house capabalities no end, and I share that feeling as we move into to trials with that knowledge firmly behind us, and a post from Rats saying the progress we should make in the next five years will far exceed the progress made in the last period.

Many different scenarios can and will happen on this journey, but I can"t help but feeling that potential move will define us in the mid term.

A nice weekend to chill, with tremendously positive vibes to our future, hope that is a feeling shared by many.

Was that her name? Thinking too about the role she had when she filled a non-exutive position on the B.O.D.

Not a n expert in the field that she had, but it seems Martin Diggle is a big improvement on that, time will tell, as always.

I see us as entering Stage 2 of our development, not many companies on AIM have achieved what we have in a relatively short term, at last dosing will begin again, after such a long gap, and if we can just reproduce in trials what we have in the clinic then rewards will start to flow like confetti.

Inanaco, the point I made about having reached an SP of 64p, all those years back, may indeed show ushow fas we could return to former glories, but IMHO it has been a big burden to carry and it was speculation that took us there, and it has seemed like adopting a defensive position for so long as we defended the fall which in reality ignored the timelines in getting there as happened to so many shares about that time.

As panda1 explained feeling relaxed, so am I, But the return to trials adds an intensity that has long been missing, the importance of data being paramount and my belief that we are well set now for a reslistic rise based on performance in trials. Yes a very exciting period coming up soon, looking forward to it intensely and with the knowledge that Vulpes have chosen this moment to join us, only adds to that feeling.

Evening barbel, I have quite a few gaps in my share chat, and seeing a few replies to Knowlesi, then even the gaps disappear.

Considering I only have person on permanant filter not too hard to work out who they are from. Is it not just diverting the good news we have had in the last couple of weeks?? My only surprise has been how long it has taken since we met Vulpes until this deal, another lesson in timelines, and has even more meaning taking into account the advisers to them and just how long these deals can take.

RG, as time passes did a streing job in making contacts and networking (something which we have heard from TF our expectations are too high and doubted these conferences were of much value to anybody. There will be more funding rounds to come as we grow into human trials, and it just feels goog that our new addition to the BOD will be so invaluanle as we grow as a company.

It feels we have truly moved on to a new level, a different stage, with many in many places keeping a very close eye on the data we will produce. A lot of credit goes to our PR company for keeping those who matter updated, and perhaps now we will see the benefits of their work specifically for PIs.

I have noted a few posts seemingly unhappy at the monies that were paid to secure such a holding, but is that not the name of the game, and look forward in the near future whilst data is collected to see our stratagy in gaining more such funds and iis in increasing their holdings here. I rather feel vulpes are in a very good position to guide the BOD on what will benefit Scancell in the short to mid term, they are here for the long term, what more do we need to hear?

So repeating myself the situation has made me feel very relaxed and the due diligence from experts in the scientific world shine brightly at such an important time. We have an amazing opportunity to plant our own garden and decorate our souls. I have my candles burning from somewhere deep inside me, and look forward to the year ahead, the ascib1/Keytruda trial, the MOD1 tril and as soon as possible the CRUK SCIB2 trial along with many other items that inanaco has mentioned as a reminder to us all.

A big well done to the PIs who have joined us in recent times, this could well be the most succesful investment you have ever made, Vupes think so, and so do I. Finance has not exactly been so esy to come across, we have learnt a few realities the last couple of years, but I like the sound of this one, and particularly what Martin Diggle can bring to the company. As ever we are expanding with top quality from many persusions, thatcan only bode well. ATB

Buys 98k

Sells 67k

Panda, feel the same, very relaxed. Didn"t take advantage of sub 6p, but perhaps good things happen to those who can wait. That"s how I feel. I enjoyed the interview with Martin Diggle, making the point too of how British Biotechs are so undervalued as to their counterparts in America. A worthy and beneficial addition to our BOD.

Good to see a few newer names posting on the BB too. Have a good weekend all.

Agree with that Rats. All that hard work in clinical development and we seem ready to go.

Just a big shame the market took us up to 64p all those years ago. Perhaps that has been the biggest hurdle we have faced, in terms of expectations and timelines.

Hi dragon. Which in fairness has been a gripe of a few LTH over the years. Now the clinical development is ready for human trials and continued clinical development in all indications, this is indeed very good news. Perhaps now we can start looking for other ii "s building holdings too.

Buys 90k

Sells 42k

And yet another great Validation!!

smpunter, thought we had lost you there. GL buddy.

Makes you wonder who else Scancell are in talks with??

Stakis, in that patients case, and others it is being used in blood cancers.

As far as side effects go, surprised they mentioned the patient had no memory of five days in intensive care. I don"t think many patients regardless of condition remember most of their time there either. Certainly not woth pneumonia.